How did GNLN's Q3 2024 EPS performance compare to expectations?
4/7/2025 06:24am
Aime
Greenlane Holdings (GNLN) reported a diluted EPS of -$2.28 for Q3 20241, which is significantly below the expected EPS. This indicates that the company's performance in Q3 2024 was notably worse than anticipated, suggesting potential operational or market challenges that impacted profitability.
GNLN Diluted EPS YoY, Diluted EPS
Source:
1.
GNLN EPS in Q3 2024
more
less
For you
What are the short-term price targets set by analysts covering Iterum Therapeutics?
What are the short-term technical indicators suggesting for Iterum Therapeutics?
Is there any unusual options activity or capital flow surrounding Iterum Therapeutics stock?
Are there any significant news or announcements expected next 90 days for Iterum Therapeutics?
How has Iterum Therapeutics' stock performed compared to the broader market recently?
Explore
Screener
What are the best stocks to buy now?
Analysis
Are KRP dividends of 0.47 per share well covered by its operating cash flow?
Learn
Advanced technical indicators and how they are calculated and utilized